Abstract:Background: Deficient interferon responses have been proposed as one of the relevant mechanisms prompting severe manifestations of COVID-19. Objective: To evaluate the interferon (IFN)-α levels in a cohort of COVID-19 patients in relation to severity, evolution of the clinical manifestations and immune/inflammatory profile. Methods: This is prospective study recruiting consecutive hospitalized patients with respiratory failure associated with SARS-COV-2 infection and matched controls. After enrollment, patients were assessed every 7 ± 2 days for additional 2 consecutive visits, for a total of 21 days. The severity of the clinical condition was ranked based on the level of respiratory support required. At each time-point blood samples were obtained to assess immune cells and mediators by multiplex immunoassay. Results: Fifty-four COVD-19 and 11 control patients matched for severity were enrolled. At recruitment, lower levels of blood IFN-α were found in COVID-19 patients compared to controls (3.8-fold difference, p < 0.01). Improvements in COVID-19 severity were paralleled by a significant increase of blood IFN-α levels. A significant increase in blood IFN-α was found over the study period in survivors (70% of the study population). A similar trend was found for blood IFN-β with IFN-β levels below the threshold of detectability in a substantial proportion of subjects. Significantly higher values of blood lymphocytes and lower levels of IL-10 were found at each time point in patients who survived compared to patients who died. In patients who clinically improved and survived during the study, we found an inverse association between IL-10 and IFN-α levels. Conclusion: The study identifies a blood immune profile defined by deficient IFN-α levels associated with increased IL-10 expression in patients progressing to severe/life threatening COVID-19 conditions, suggesting the involvement of immunological pathways that could be target of pharmacological intervention. Clinical Trial Registration: ClinicalTrials.gov identifier NCT04343053.

Potential protective role of interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) in COVID-19

Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

Association between polymorphisms in TLR3, TICAM1 and IFNA1 genes and covid-19 severity in Southern Brazil

Differential Leukocyte Expression of IFITM1 and IFITM3 in Patients with Severe Pandemic Influenza A(H1N1) and COVID-19

Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome

Interferon-induced transmembrane protein 3 (IFITM3) limits lethality of SARS-CoV-2 in mice

Type I and type III interferons: From basic biology and genetics to clinical development for COVID-19 and beyond

Interferon-stimulated genes and their antiviral activity against SARS-CoV-2

Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia

Specialized interferon action in COVID-19

An Evaluation of Type 1 Interferon Related Genes in Male and Female-Matched, SARS-CoV-2 Infected Individuals Early in the COVID-19 Pandemic

Association of the IFNG +874T/A Polymorphism with Symptomatic COVID-19 Susceptibility

Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity

Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection

Blood Interferon-α Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients

Type I Interferonopathy among Non-Elderly Female Patients with Post-Acute Sequelae of COVID-19

Interferon gene expression declines over time post-COVID infection and in long COVID patients

Identification of immune-related hub genes and potential molecular mechanisms involved in COVID-19 via integrated bioinformatics analysis

Integrated Interactome and Transcriptome Analysis Reveals Key Host Factors Critical for SARS-CoV-2 Infection.

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

More rapid blood interferon α2 decline in fatal versus surviving COVID-19 patients